Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs, Including Parkinson’s Disease

November 21, 2025 0

Aspen Neuroscience Aspen Neuroscience, Inc. – a clinical-stage biotechnology company pioneering autologous regenerative therapies, announced the closing of a $115 million Series C financing round. This significant investment will fuel the continued clinical development of Aspen’s lead program, ANPD001, for moderate to advanced Parkinson’s disease. The Series C round was co-led by OrbiMed, ARCH Venture Partners, Frazier Life Sciences, and …

Regeneron: DB-OTO Results in Sustained Improvement in Hearing and Speech...

VectorY Therapeutics and Shape Therapeutics, both private firms Announce Option...

Helping Your Pets to be Healthy and Live Longer

Praxis Precision Medicines Radiant Study with Vormatrigine

ARS Pharmaceuticals Announces FDA Approval of neffy® for Type I...

Nuvig Therapeutics Announces $161 Million Series B Financing, Plus Its...

Iterum Therapeutics Receives US FDA Approval of ORLYNVAH™ for the...

The United States FDA Approved Astellas’ product VYLOY in Combination...

U.S. FDA Approves AbbVie’s VYALEV™ for Adults Living with Advanced...

Novo Nordisk Launches New Initiative To Prevent Childhood Obesity In...

The FDA Approved IntraBio Product AQNEURSA As the only treatment...

Jeune Aesthetics: Reversing the Biology of Aging Skin to Meet...

Galderma Receives U.S. FDA Approval for Nemluvio® for Adult Patients...

SCG Cell Therapy: FDA Approved IND Application of Product SCG142...

Mitsubishi Tanabe Pharma America Announced the Presentations of its ND0612...

AstraZeneca: The U.S. FDA Approved IMFINZI in Combination with Carboplatin...

Regeneron: Improved Hearing to Normal Levels in a Child with...

INmune Bio Inc. Update on Two Alzheimer Disease Patients Who...

Cerevel Therapeutics Announces Positive Results for Tavapadon in Phase 3...

Impacting News

Novo Nordisk Launches Introductory Self-Pay Offer for Wegovy® and Ozempic® for $199 Per Month

November 18, 2025 0

Novo Nordisk in the NEWS On Monday, November 17, 2025, Novo Nordisk (NVO) announced that Wegovy® (semaglutide) injection 0.25 …

Vertex Pharmaceuticals Never Stops Bringing New Data To Heal Untreated Severe Diseases

November 12, 2025 0

Vertex Pharmaceuticals in the NEWS On November 8, 2025, Vertex Pharmaceuticals Incorporated (VRTX) announced updated data for …

Cogent Biosciences Reports Positive Results from Bezuclastinib Peak Phase 3 Trial in Gastrointestinal Stromal Tumors

November 11, 2025 0

Cogent Biosciences On November 10, 2025, Cogent Biosciences (COGT) reported positive data from its Phase 3 …

Ionis Pharmaceuticals Groundbreaking Pivotal Study Results of Olezarsen for Severe Hypertriglyceridemia Presented as Late Breaker at AHA Scientific Sessions

November 10, 2025 0

Ionis Pharmaceuticals On November 8, 2025, Ionis Pharmaceuticals (IONS) announced positive results from the pivotal Phase …

The U.S. FDA Approved GSK Product Blenrepis for Treatment of Relapsed/Refractory Multiple Myeloma

October 24, 2025 0

GSK US FDA Approval Yesterday, October 23, 2025, GSK plc (GSK) announced the United States Food …

The FDA Approves Roche’s Gazyva/Gazyvaro for the Treatment of Lupus Nephritis

October 20, 2025 0

Roche in the NEWS Roche (RHHBY) announced Food and Drug Administration approval of Gazyva®/Gazyvaro®(obinutuzumab) for the …

Trick or Trade

Cogent Biosciences Has Excellent NEWS

November 24, 2025 0

Cogent Biosciences Excellent NEWS Cogent Biosciences (COGT) develops precision therapies for patients with genetically defined diseases. …

In Data Presented at the European Association for the Study of Diabetes and NEUROdiabetis Meetings, Lexicon Pharmaceuticals Product Pilavapadin Provided Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain.

September 18, 2025 0

Lexicon Pharmaceuticals in the NEWS Yesterday, September 17, 2025, Lexicon Pharmaceuticals (LXRX) announced the presentation of …

The FDA is Taking Concrete Steps to Reduce Opioid Misuse, Addiction and Overdose Strengthening Guidance on Their Appropriate Use

September 11, 2025 0

Xenon Pharmaceuticals A Company Treating Chronic Pain Xenon Pharmaceuticals (XENE) - a neuroscience-focused biopharmaceutical company dedicated …

Alnylam’s Presentation In Early September

August 28, 2025 0

Alnylam Pharmaceuticals Presentations In early September 2025, Alnylam Pharmaceuticals (ALNY) will present two investor conferences. The …

Klotho Neurosciences to Expand Development Programs Beyond Neurology

July 28, 2025 0

Klotho Neurosciences to Pursue Technologies to Improve Brain Function, Muscle Strength, Bone Health, and Other Longevity …

Question & Answer About Kiniksa Pharmaceuticals

July 17, 2025 0

Q & A: Kiniksa Pharmaceuticals Q: Do you have any recent news from Kiniksa Pharmaceuticals? A: …

Today’s Highlights

Merck to Acquire Cidara Therapeutics Inc Diversifying Its Portfolio To Include Late-Phase Antiviral Agent

November 14, 2025 0

Merck to Acquire Cidara Therapeutics Merck (NYSE: MRK), known as MSD outside of the United States …

Cidara Therapeutics Provides Corporate Update and Reports Q3 2025 Results

November 7, 2025 0

Cidara Therapeutics Q3 Financial Results SAN DIEGO, November 06, 2025, Cidara Therapeutics, Inc. (CDTX) reported financial …

Knowing What Cidara Therapeutics is Doing for the Seasonal Flu

October 28, 2025 0

Cidara Therapeutics Cidara Therapeutics (CDTX) is using its proprietary Cloud break® platform to develop novel drug-Fc …

BridgeBio Pharma Reported Positive Phase 3 Results from FORTIFY the Phase 3 Pivotal Study of BBP-418 in People with Limb-Girdle Muscular Dystrophy Type 2I/R9

October 27, 2025 0

BridgeBio Pharma BridgeBio Pharma, Inc. is a new type of biopharmaceutical company founded to discover, create, …

Why GRAL is Moving UP More Than Usual Today

October 16, 2025 0

Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia …

Akero Therapeutics Announced It Entered into a Definitive Agreement to be Acquired by Novo Nordisk

October 9, 2025 0

Akero Therapeutics Acquisition Agreement Today, October 9, 2025, Akero Therapeutics (AKRO) announced that it entered into …

Latest Articlesddd

Cogent Biosciences Has Excellent NEWS

November 24, 2025 0

Cogent Biosciences Excellent NEWS Cogent Biosciences (COGT) develops precision therapies for patients with genetically defined diseases. …

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs, Including Parkinson’s Disease

November 21, 2025 0

Aspen Neuroscience Aspen Neuroscience, Inc. – a clinical-stage biotechnology company pioneering autologous regenerative therapies, announced the …

Novo Nordisk Launches Introductory Self-Pay Offer for Wegovy® and Ozempic® for $199 Per Month

November 18, 2025 0

Novo Nordisk in the NEWS On Monday, November 17, 2025, Novo Nordisk (NVO) announced that Wegovy® (semaglutide) injection 0.25 …

Merck to Acquire Cidara Therapeutics Inc Diversifying Its Portfolio To Include Late-Phase Antiviral Agent

November 14, 2025 0

Merck to Acquire Cidara Therapeutics Merck (NYSE: MRK), known as MSD outside of the United States …

Vertex Pharmaceuticals Never Stops Bringing New Data To Heal Untreated Severe Diseases

November 12, 2025 0

Vertex Pharmaceuticals in the NEWS On November 8, 2025, Vertex Pharmaceuticals Incorporated (VRTX) announced updated data for …

Cogent Biosciences Reports Positive Results from Bezuclastinib Peak Phase 3 Trial in Gastrointestinal Stromal Tumors

November 11, 2025 0

Cogent Biosciences On November 10, 2025, Cogent Biosciences (COGT) reported positive data from its Phase 3 …

Ionis Pharmaceuticals Groundbreaking Pivotal Study Results of Olezarsen for Severe Hypertriglyceridemia Presented as Late Breaker at AHA Scientific Sessions

November 10, 2025 0

Ionis Pharmaceuticals On November 8, 2025, Ionis Pharmaceuticals (IONS) announced positive results from the pivotal Phase …

Cidara Therapeutics Provides Corporate Update and Reports Q3 2025 Results

November 7, 2025 0

Cidara Therapeutics Q3 Financial Results SAN DIEGO, November 06, 2025, Cidara Therapeutics, Inc. (CDTX) reported financial …

Knowing What Cidara Therapeutics is Doing for the Seasonal Flu

October 28, 2025 0

Cidara Therapeutics Cidara Therapeutics (CDTX) is using its proprietary Cloud break® platform to develop novel drug-Fc …

BridgeBio Pharma Reported Positive Phase 3 Results from FORTIFY the Phase 3 Pivotal Study of BBP-418 in People with Limb-Girdle Muscular Dystrophy Type 2I/R9

October 27, 2025 0

BridgeBio Pharma BridgeBio Pharma, Inc. is a new type of biopharmaceutical company founded to discover, create, …

The U.S. FDA Approved GSK Product Blenrepis for Treatment of Relapsed/Refractory Multiple Myeloma

October 24, 2025 0

GSK US FDA Approval Yesterday, October 23, 2025, GSK plc (GSK) announced the United States Food …

The FDA Approves Roche’s Gazyva/Gazyvaro for the Treatment of Lupus Nephritis

October 20, 2025 0

Roche in the NEWS Roche (RHHBY) announced Food and Drug Administration approval of Gazyva®/Gazyvaro®(obinutuzumab) for the …

U.S. FDA Approves Boehringer Ingelheim’s JASCAYD® (nerandomilast) Tablets as First New Treatment for Adults with Idiopathic Pulmonary Fibrosis

October 16, 2025 0

Boehringer Ingelheim USFDA Approval Boehringer Ingelheim JASCAYD® (nerandomilast) tablets are approved by the U.S. FDA as …

Why GRAL is Moving UP More Than Usual Today

October 16, 2025 0

Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia …

Regeneron: DB-OTO Results in Sustained Improvement in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

October 14, 2025 0

The Great Story from Regerneron Pharmaceuticals Regeneron Pharmaceuticals (REGN) announced updated data for the Company’s investigational …

Akero Therapeutics Announced It Entered into a Definitive Agreement to be Acquired by Novo Nordisk

October 9, 2025 0

Akero Therapeutics Acquisition Agreement Today, October 9, 2025, Akero Therapeutics (AKRO) announced that it entered into …

U.S. FDA Lifts Clinical Hold on NUZ-001, Neurizon® Lead Investigational Therapy for ALS

October 6, 2025 0

Neurizon Therapeutics in the NEWS Today October 6, 2025, from Melbourne, Australia: Neurizon Therapeutics Limited (ASX: …

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

September 29, 2025 0

Genmab in the NEWS Denmark; UTRECHT, The Netherlands; Today, Genmab (GMAB) and Merus (MRUS) announced that …

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease

September 25, 2025 0

uniQure in the NEWS On September 24, 2025, uniQure N.V. (QURE) - a gene therapy company advancing transformative …